Literature DB >> 22683308

Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia.

Xin Li1, Xiaoqing Li, Wei Xie, Yanjie Hu, Juan Li, Wen Du, Wei Liu, Hongrui Li, Xiangjun Chen, Lannan Zhang, Junfeng Wang, Shiang Huang.   

Abstract

Diagnostic cytogenetic and molecular analysis is recognized as the most valuable prognostic factor in acute myeloid leukemia (AML). Among 2516 consecutive Chinese patients with de novo AML, 2308 patients had successful cytogenetic results including 61 subclasses of cytogenetic abnormalities and 27 kinds of additional cytogenetic abnormalities. The incidence of t(15;17)(q22;q12) was highest (16.7% of 2308 patients), followed by t(8;21)(q22;q22) (15.1%), trisomy 8 (5.5%), loss of Y (4.5%), trisomy 21 (2.4%), inv(16)(p13q22) or t(16;16)(p13;q22) (2.1%), etc. In comparison to children, adults had higher incidence of normal karyotype (41.5% vs. 29.1%, P<0.001) and lower incidences of t(8;21)(q22;q22) (13.4% vs. 25.8%, P<0.001), t(9;11)(p22;q23) (0.2% vs. 1.2%, P=0.001) and other 11q23 rearrangements (1.0% vs. 3.4%, P<0.001). Among 349 AML patients with t(8;21)(q22;q22), 310 (35.5%) were found in 873 patients with M2. The t(15;17)(q22;q12) was exclusively observed in 386 (71.0%) of 544 patients with M3. In 48 AML patients with inv(16)(p13q22) or t(16;16)(p13;q22), 42 (15.2%) were detected in 276 patients with M4. Our study displayed the cytogenetic characteristics in a large series of Chinese patients with de novo AML. Our results revealed the similarities and differences of cytogenetic abnormalities existing between Chinese and western AML patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683308     DOI: 10.1016/j.bcmd.2012.05.007

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  Geographic heterogeneity of the AML1-ETO fusion gene in Iranian patients with acute myeloid leukemia.

Authors:  Saeedeh Ghazaey Zidanloo; Abasalt Hosseinzaeh Colagar
Journal:  Rep Biochem Mol Biol       Date:  2014-10

2.  Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.

Authors:  Xiaofei Zhou; Sharon Friedlander; Erik Kupperman; Farhad Sedarati; Shingo Kuroda; Zhaowei Hua; Ying Yuan; Yuka Yamamoto; Douglas V Faller; Kazue Haikawa; Katsuhiko Nakai; Sharon Bowen; Yi Dai; Karthik Venkatakrishnan
Journal:  Clin Transl Sci       Date:  2021-02-02       Impact factor: 4.689

3.  A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors.

Authors:  Qing Li; Zhaodong Zhong; Chen Zeng; Li Meng; Chunrui Li; Yi Luo; Hongxiang Wang; Weiming Li; Jue Wang; Fanjun Cheng; Anyuan Guo; Songya Liu; Caibao Jin; Xiaojian Zhu; Yong You; Ping Zou
Journal:  Oncotarget       Date:  2016-09-06

4.  Cytogenetic and mutational analysis and outcome assessment of a cohort of 284 children with de novo acute myeloid leukemia reveal complex karyotype as an adverse risk factor for inferior survival.

Authors:  Xi Chen; Xingjuan Wang; Hu Dou; Zhenzhen Yang; Junqin Bi; Yi Huang; Ling Lu; Jie Yu; Liming Bao
Journal:  Mol Cytogenet       Date:  2021-05-19       Impact factor: 2.009

5.  Genetic Profiles and Risk Stratification in Adult De Novo Acute Myeloid Leukaemia in Relation to Age, Gender, and Ethnicity: A Study from Malaysia.

Authors:  Angeli Ambayya; Anthony V Moorman; Jameela Sathar; Jeyanthy Eswaran; Sarina Sulong; Rosline Hassan
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

6.  Coexistence of p210BCR-ABL and CBFβ-MYH11 fusion genes in myeloid leukemia: A report of 4 cases.

Authors:  Yuan-Yuan Wang; Wen-Jing Ding; Feng Jiang; Zi-Xing Chen; Jian-Nong Cen; Xiao-Fei Qi; Jian-Ying Liang; Dan-Dan Liu; Jin-Lan Pan; Su-Ning Chen
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.